Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) have received an average rating of “Buy” from the sixteen research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, thirteen have assigned a buy rating and two have given a strong buy rating to […]